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Abstract: Depression is a neuropsychiatric disorder affecting a huge percentage of the active population especially in  
developed countries. Research has devoted much of its attention to this problematic and many drugs have been developed 
and are currently prescribed to treat this pathology. Yet, many patients are refractory to the available therapeutic drugs, 
which mainly act by increasing the levels of the monoamines serotonin and noradrenaline in the synaptic cleft. Even in  
the cases antidepressants are effective, it is usually observed a delay of a few weeks between the onset of treatment and  
remission of the clinical symptoms. Additionally, many of these patients who show remission with antidepressant therapy 
present a relapse of depression upon treatment cessation. Thus research has focused on other possible molecular targets, 
besides monoamines, underlying depression. Both basic and clinical evidence indicates that depression is associated with 
several structural and neurochemical changes where the levels of neurotrophins, particularly of brain-derived neurotrophic 
factor (BDNF), are altered. Antidepressants, as well as other therapeutic strategies, seem to restore these levels. Neuronal 
atrophy, mostly detected in limbic structures that regulate mood and cognition, like the hippocampus, is observed in  
depressed patients and in animal behavioural paradigms for depression. Moreover, chronic antidepressant treatment   
enhances adult hippocampal neurogenesis, supporting the notion that this event underlies antidepressants effects. Here we 
review some of the preclinical and clinical studies, aimed at disclosing the role of neurotrophins in the pathophysiological 
mechanisms of depression and the mode of action of antidepressants, which favour the neurotrophic/neurogenic hypothesis. 
Keywords: Antidepressants, BDNF, depression, hippocampal neurogenesis, neuropsychiatric disorders, stress, Val66Met   
polymorphism, VGF. 
HYPOTHESIS OF DEPRESSION: A GENERAL 
OVERVIEW 
  Depression is an illness affecting a great number of peo-
ple worldwide. This problematic involves not only the indi-
viduals, but also their families and the surrounding social 
environment. Taking as a reference the United States of 
America, it is proposed that about one in six individuals will 
deal with clinically diagnosed symptoms of depression dur-
ing their lifetime [1]. Apart from the disheartened mood, the 
loss of interest or pleasure, feelings of guilt or worthlessness, 
disturbed sleep or appetite, low energy, poor concentration 
and suicidal intentions are some of the principal symptoms 
observed in depressed patients [2, 3]. This unpleasant “state 
of mind” may be related with working conditions, self-
perceived stress, anxiety and quality of life [4], however, it’s 
curious and intriguing why predisposition to develop depres-
sion is higher in certain persons than others. Levinson [5] 
proposed that a great part of depression is genetically deter-
mined. In this meta-analysis there are positive associations 
with some psychiatric disorders (bipolar disorder, suicidal 
behaviour, and depression-related personality traits) and a 
polymorphism in the serotonin transporter promoter region 
(5-HTTLPR). Nowadays, it’s assumed that a complex inter-
action between genetic, biochemical and environmental 
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factors may be underlying the causative aetiology of this 
disorder [3]. 
  The study of depression keeps being a challenge for those 
who want to reveal the real mechanism of this psychiatric 
disorder. Indeed, in spite of the long history of research in 
this field, the science behind mood regulation remains prac-
tically unknown and the development of efficient drugs is far 
from being satisfactory [6-8]. One of the reasons appointed 
to this lack of knowledge is the difficulty associated with the 
observation of pathological changes within the human brain 
[9]. At the moment, studies on humans rely on the evaluation 
of cases in which certain brain structures are absent (acci-
dently or not) or on post-mortem tissues which, by law, are 
only available for experimental tests several hours after 
death. In this matter, the development of animal models of 
depression has helped to attain some important achieve-
ments. However, to be considered a valid animal model of 
depression it needs to satisfy some requirements, initially 
proposed by McKinney and Bunny [10, 11]. Its undeniable 
the value of animal models of depression in the identification 
and validation of monoamine-based antidepressant com-
pounds, although inherent limitations of animals models in 
comparison to the manifestations of such a complex disease 
in humans must be accepted [10]. Despite the difficulty of 
researching in this area, scientists have been improving their 
knowledge and acquiring new methods and approaches, test-
ing new concepts and drugs that certainly will be useful in 
the future. Neurotrophins in Depression  Current Neuropharmacology, 2011, Vol. 9, No. 4    531 
  The monoamine hypothesis of depression was the most 
accepted by the scientific community [12-14] which de-
fended that this illness was caused by a deficit in the neuro-
transmission of serotonin and noradrenaline and that it could 
be reversed by drugs (namely antidepressants) that promote 
the increase of these molecules in the synaptic cleft [9, 15, 
16]. However, this theory was not sufficient to explain all the 
mechanisms beyond depression. Antidepressants acting   
either by blockage of the reuptake of monoamines or by   
inhibition of their degradation at the synaptic cleft promoted 
an immediate increase of serotonin and noradrenaline trans-
mission [9, 15, 16] but the antidepressant effect was only 
saw after a few weeks of treatment. Monoamine depletion 
studies demonstrate decreased mood in subjects with a   
family history of major depression (MD) and in drug-free 
patients with MD in remission, but do not decrease mood in 
healthy humans [17, 18]. So, it soon became obvious that 
depression involves further modifications besides those at 
the monoamine system. At the same time several studies 
emerged to assess new pharmacological models that may 
help to understand the mechanisms and pathophysiological 
changes leading to a depressive behaviour.  
THE NEUROTROPHIC HYPOTHESIS OF DEPRES-
SION 
  Several studies have led to the formulation of the Neu-
rotrophic Hypothesis of Depression, which postulates that 
low levels of brain-derived neurotrophic factor (BDNF) lead 
to a depression condition [19, 20]. Neurotrophins are growth 
factors with crucial roles in the formation and plasticity of 
neuronal networks [21]. The neurotrophin family include 
nerve growth factor (NGF), BDNF, neurotrophin-3 (NT-3) 
and neurotrophin-4 (NT-4). They are initially synthesized as 
precursor proteins (proneurotrophins), which are processed 
extracellular or intracellularly to be secreted mostly in a ma-
ture, biologically active form [22-26]. The neurotrophins 
show binding specificity for particular tyrosine kinase recep-
tors (Trk), and non-specificity for the p75 neurotrophin re-
ceptor (p75NTR) (see for review [27]). In particular, pro-
BDNF preferentially activates p75NTR receptor to mediate 
programmed neuronal death [28], to decrease dendrite com-
plexity and spine density in hippocampal neurons [29], and 
to induce long-term depression of synaptic transmission [30, 
31]. On the contrary, mature BDNF (mBDNF) selectively 
activates TrkB, a member of the tyrosine kinase receptors 
family, to promote survival and differentiation, increasing 
the branching of axons and dendrites and stabilizing synaptic 
contacts [32]. Thus, due to the essential role of BDNF   
for cell differentiation, nerve growth and neuronal survival  
it has been implicated in several brain diseases, including 
depression.  
  In what concerns to stress, a prominent cause of depression,  
it is well established its relation with low levels of BDNF  
expression. For example, stress caused by immobilization   
decreases the expression of this neurotrophin in the   
hippocampus [33]. Nowadays, this vision has been modified,  
highlighting the role of BDNF (the most studied neurotro- 
phin) in the adaptation of neural networks that are   
responsible for different aspects of mood regulation [19, 34,  
35]. In the last few years, solid evidences have been suggest- 
ing an important role of neurotrophins in mood regulation  
and antidepressant-like behaviour [36, 37]. Indeed, depressed  
patients have decreased serum levels of BDNF [38] while the  
treatment with antidepressants promotes an increase in these  
levels [38]. However, these observations are not totally   
accepted as a proof of BDNF involvement since neurotro- 
phins are mainly involved in the neural development,   
function and plasticity [39-45] which are some of the points  
of action of the treatment with antidepressants [19, 46].   
Several authors have reported structural and functional   
BDNF-induced modifications of neuronal networks, which   
allowed their re-organization as a response to inputs from the  
environment [43, 47, 48]. These effects were produced by  
binding and activation of tyrosine kinase receptor subtype B  
(TrkB) leading to changes in cell shape and gene trans- 
cription [47]. Antidepressants were also shown to be able to  
interfere with neuronal plasticity [19, 46] being the neuro- 
genesis the most interesting phenomenon within this field   
[49]. So far, neuroscientists have been proposing new   
mechanistic hypothesis for depression, in search for clues for  
understanding its pathophysiology. A different point of view  
actually discusses the balance between neuronal death and  
neurogenesis as an etiological cause of this pathology [50,  
51]. In fact, neurogenesis is a possible phenomenon in adults  
[52-54] and neurotrophins are important for nervous cells   
formation and differentiation [55, 56]. Several studies have  
been proposed to test some of these theories relating the   
balance between neuronal death and neurogenesis, but most  
of them still lack experimental verification [57, 58]. In   
rodent hippocampus, for example, it has been observed that  
neurogenesis is increased by antidepressant treatments [46,  
59-61]. Additionally, several studies correlate antidepressants  
administration with neurotrophins expression. Interestingly,  
BDNF expression was dependent on a chronic treatment [62]  
which was very curious given the time that antidepressants  
need to have a therapeutic effect. In fact it is possible that,  
somehow, neurotrophins may also have functions in the   
regulation of transmitter release. Actually, several studies   
have reported this role. After Lohof and colleagues [63]   
demonstrated a presynaptic mechanism of enhancement of  
synaptic transmission promoted by BDNF and NT-3, other  
authors reached similar conclusions [64]. Later it was found  
that dysregulation of presynaptic TrkB (truncated form) in  
the hippocampal neurons reduced the amount of BDNF- 
induced neurotransmitter release [65, 66] and that the treat- 
ment of cultured hippocampal neurons with BDNF promoted  
a decrease in paired pulse facilitation [67-68]. Tyler and   
colleagues proposed that BDNF alters the mode of vesicle  
retrieval from a slow complete fusion with membrane [69]  
to a faster vesicle retrieval without complete fusion [70]   
modulated by presynaptic voltage-dependent Ca
2+ channels.  
These effects appear to be related with TrkB-dependent   
phosphorylation [71-73]. Consequently, the number of   
docking sites increases promoting neurotransmitters vesicle’s  
mobilization to the active zone. In summary it appears   
that neurotrophins, and in particular BDNF are engaged   
in the pathophysiology of several neurologic diseases,   
including depression, by acting through several mechanistic  
approaches implicated in neuronal death, neurogenesis,   
control of neurotransmitters release or even the induction of  
certain neuropeptides, as VGF (non-acronym). Indeed, the   
finding of increases in the expression of BDNF and of its  
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marked the beginning of this line of research [38, 62, 74] and  
of the neurotrophic hypothesis of depression. 
BDNF IN DEPRESSION: PRECLINICAL AND 
CLINICAL EVIDENCES 
Preclinical Evidences  
Regulation of BDNF in Animal Models of Stress  
  It is widely known that stress is a risk factor for major 
depression in individuals with genetic vulnerability. Basic 
research has used animal models which imply stress to 
model such complex multi-syndrome psychiatric illnesses 
like major depression because they induce or mimic some of 
their clinical symptoms: anhedonia, sleep disturbances, in-
creased corticosterone levels, etc. Thus, numerous studies 
have focused in the role of BDNF in different animal models 
of stress and antidepressant drugs response. In general, most 
of the studies have shown that acute or chronic stress in-
duced by different types of stressors, such as immobilization, 
unpredictable, footshock, social isolation, social defeat, ma-
ternal deprivation, restraint and swim stress decrease BDNF 
levels in the hippocampus (see Table 1 for references). In 
fact, significant reductions of BDNF messenger RNA 
(mRNA) were observed in CA1 and CA3 pyramidal cell 
layers but the greatest effects were found in the dentate gyrus 
granule cell layer [75]. Given that in this last layer is where 
adult neurogenesis process occurs, it is suggested a relation-
ship between BDNF and neurogenesis (see below in the   
section Hippocampal Neurogenesis). Thus, as cited above, 
BDNF appears to mediate neurogenesis in dentate gyrus and 
neuronal atrophy seen with stressful conditions seems to 
occur in CA3 pyramidal cells. Indeed, stress reduces the 
length and number of branch points of CA3 neurons in the 
hippocampus [76]. Atrophy or remodelling of CA3 neurons 
could contribute to the reduction in hippocampal volume 
reported in depressed patients [77, 78]. However, there is no 
common consensus in the literature about the decrease of 
BDNF expression in stress-related animal models. For ex-
ample, chronic restraint stress for 21 days did not modify 
BDNF expression in Kuroda and McEwen’s studies [79] 
(Table 1). In contrast, a few years later, Murakami and co-
workers [80], applied the same stress paradigm and a signifi-
cant decrease of BDNF expression in the hippocampus was 
found. Such discrepancy also occurs in several studies that 
also reported no effects or even increase of BDNF levels in 
the hippocampus following exposure to chronic stress [81-
87] (Table 1). The authors argue that the differences found 
reside in the stress protocols applied in each study. In con-
clusion, the effects of stress on BDNF mRNA expression in 
the hippocampus appear to be dependent on several factors: 
(i) the type of stressor; its intensity, duration, frequency, 
number of exposures, etc. [88, 89]; (ii) the procedure used to 
quantify BDNF levels and (iii) the isoform or isoforms 
measured in each assay [25, 90]. In addition to physical 
stress models, there are also available data about corticoster-
one levels modulation and BDNF. It is widely known that 
stress increases plasma and adrenal corticosterone levels [80, 
91] and several studies reported an inverse correlation be-
tween stress/corticosterone levels and BDNF expression in 
the hippocampus. Thus, corticosterone administration (which 
mimics stress situation) decreases BDNF levels in the hippo-
campus [33, 80, 92-95]. In contrast, in adrenalectomized 
animals, hippocampal BDNF values were restored to base-
line levels [33, 95]. However, stress in adrenalectomized rats 
decreases BDNF expression in the dentate gyrus, where main 
neurogenesis process occurs, but not in CA1 and CA3 layers 
of the hippocampus [33]. Thus, in summary, although with 
some significant disagreements, it seems that there is a corre-
lation between stress induction and BDNF decreased expres-
sion mainly in the dentate gyrus as it is shown in Table 1 and 
in less extension in CA3 and CA1 layers.  
Stress and BDNF, Possible Mechanisms 
  What are the possible mechanisms underlying the puta-
tive down-regulation of BDNF expression due to stress ex-
posure? As we mentioned before several studies have dem-
onstrated that stress causes impaired neurogenesis and atro-
phy in certain limbic structures, particularly the hippocam-
pus, and that BDNF down-regulation is one of the events that 
occurs. However, the precise mechanism underlying this 
down-regulation has not been fully understood. The studies 
available suggest that stress induces lasting down-regulation 
of BDNF transcripts III and IV and robust chromatin modifi-
cation [96, 97]. So, stressful experience would decrease lev-
els of specific BDNF isoforms and could contribute to the 
atrophy of limbic structures, including that in the hippocam-
pus that has been observed in depressed patients. However, 
this BDNF regulation system seems to be very complex be-
cause several factors influence it. Thus, it has been suggested 
that glucocorticoids modulate BDNF signalling pathways. It 
has already been mentioned that high adrenal-glucocorticoid 
levels, which is one of the hallmark endocrine responses to 
stress, decreases BDNF expression. The mechanisms under-
lying these phenomena needs to be studied further, but it has 
been suggested that glucocorticoid inhibits the BDNF-
dependent up-regulation of synaptic proteins via  suppress- 
ing the activation of Mitogen-Activated Protein Kinases/ 
Extracellular signal-Regulated Kinases (MAPK/ERK) path-
way [98]. Another line of evidence supporting a role of 
BDNF in depression is the trophic effect of BDNF on the 
serotoninergic system. For example, the antagonism of sero-
tonin 2A receptors (5-HT2A) by ketanserin partially blocks 
the effect of stress on BDNF expression [99, 100], suggest-
ing that serotonin is a key mediator, an idea congruent with 
the numerous findings about both serotonin and the 5-HT2A 
receptor in the aetiology and treatment of depression and 
other affective disorders [101, 102]. Cytokines have equally 
recently received much attention in depression field also in 
relation with BDNF. Studies reveal that the interleukin-1 
(IL-1), cytokine, which is implicated in the development of 
depressive-like behaviour [103], contributes to BDNF down-
regulation. Moreover, the blockade of IL-1 receptors pre-
vented the stress-induced decrease of BDNF [104, 105]. This 
effect on BDNF transcription could be directly or indirectly 
mediated by the inhibition of the phosphorylation of cAMP-
related element binding protein (CREB, a major transcription 
factor managing the gene expression of the plasticity-related 
molecules) [106] or by increasing serotonin extracellular 
levels in the hippocampus [107], respectively. Together, it 
suggests that additional components of the stress response 
may also contribute to the observed changes in BDNF.  
  As stated before, most of the studies until now have   
focused on the effect of BDNF expression level in the Neurotrophins in Depression  Current Neuropharmacology, 2011, Vol. 9, No. 4    533 
Table 1.  Regulation of Hippocampal BDNF Expression 
Factor Treatment  Duration  BDNF  Expression  References 
STRESS 
1, 7 days, (45 minutes/day)  [33] 
45 minutes  [74, 99]  Immobilization 
8 hours 
 
[327] 
10 days, 4-15 weeks    [62, 328, 329, 330-332] 
Unpredictable 
19 days, 7-11 weeks  =  [333, 91, 83-85, 87] 
Footshock  60 minutes, (0,4 mA)   [334] 
Social isolation  6 hours   [104] 
10 minutes   [335] 
Social defeat 
5 weeks   [86] 
Maternal deprivation  24 hours, P9   [336] 
Swim stress  10 minutes/day, 14 days   [337] 
4 hours/day, 3 days   [338] 
= [79] 
6 hours/day, 21 days 
 [80] 
Restraint 
1 hour/day, 7 days   [82] 
CORTICOSTERONE  Acute, 7 days    [33, 95, 339-340] 
ADRENALECTOMY     [339-340] 
ANTIDEPRESSANTS 
NRIs 
Reboxetine 2-14  days   [341] 
14, 21 days   [62,  342-343] 
Desipramine 
Acute, 14 days  =  [344, 345] 
Maprotiline  Acute, 14 days  =  [344, 345] 
SSRIs 
Acute, 14, 21 days    [62, 332, 343, 345-346] 
7 days  =  [320, 342, 344, 346-347]  Fluoxetine 
4 days   [346] 
Paroxetine  Acute, 14 days   [345] 
Sertraline  Acute, 14, 21 days   [62,  345] 
Citalopram  2, 9 days   [341,  348] 
SNRIs 
Dual 
Venlafaxine  28, 35 days   [83,  349] 
Tricyclics 
14, 20, 27 days    [332, 338, 350-351] 
Imipramine 
28 days  =  [83] 
Amitriptyline 21  days   [351,  352] 
Atypical 
21 days   [74] 
Mianserine 
Acute, 14 days  =  [345] 
Tianeptine 21  days  =  [79] 
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Table 1. contd…. 
Factor Treatment  Duration  BDNF  Expression  References 
MOR AGONISTS 
Morphine, DAMGO
1 Acute   [160,  353] 
MAOI 
Acute, 2, 14-21 days    [74, 342, 345, 350, 354] 
Tranylcypromine 
4, 14, 21 days  =  [344] 
Benzodiazepine 
Olanzapine 35  days   [349] 
acute   [123] 
Ketamine 
acute, 7, 14 days  =  [114, 91] 
ECT  10, 21 days   [344] 
Exercise  1-28 days    [341, 350, 354-358] 
1, 7 days  =  [122] 
Lithium 
14-28 days   [122,  124] 
BDNF, brain-derived neurotrophic factor; ECT, electroconvulsive shock treatment; MAOI, monoamine oxidase inhibitor; NRIs, noradrenaline reuptake inhibitors; SSRIs, serotonin 
selective reuptake inhibitors; SNRIs, serotonin and noradrenaline reuptake inhibitors, 
1 [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin. 
hippocampus. However, BDNF is modulated under stress 
conditions in other brain areas, such as prefrontal cortex. 
Thus, it has been shown that stress by immobilization pro-
duces a significant increase in BDNF expression in prefron-
tal cortex and the metabotropic glutamate 2/3 receptor 
(mGluR2/3) agonist, LY35740, attenuates the immobiliza-
tion stress-induced increase in BDNF mRNA expression in 
the prefrontal cortex [108]. Therefore, we conclude that 
stress modulates BDNF expression in the hippocampus and 
that modulation is affected by several intermediate factors 
and produced by different signalling pathways. In addition, 
BDNF expression in other areas apart from hippocampus 
may play an important role in mood that may be taken in 
consideration. 
Antidepressant-Like Effects of BDNF 
  Following the idea that stressful situations down-regulate 
BDNF, the effect of BDNF infusion on depressive-like be-
havioural tests was evaluated. Thus, in 1996, Suiciak and 
colleagues [109] showed that infusion of BDNF either in-
tracerebroventricularly (i.c.v.) or directly into the rat mid-
brain (periaqueductal gray matter and dorsal and median 
raphe nuclei) produced analgesia and, interestingly, in-
creased the activity of the monoaminergic systems. Indeed, 
BDNF infusion promotes the function, sprouting and growth 
of serotonin-containing neurons in the brain of adult rats 
[110] and increases noradrenaline levels in several brain ar-
eas including the hippocampus [109]. These effects of BDNF 
on serotoninergic and noradrenergic system link the classical 
monoaminergic hypothesis of depression with the neurotro-
phic theory. Two later studies demonstrated that both acute 
or subchronic (3-7 days) BDNF infusion into the hippocam-
pus (dentate gyrus and CA3 layer) or in the midbrain, pro-
duces an antidepressant-like effect in two behavioural mod-
els of depression, the learned helplessness and the forced 
swimming test paradigms. In these tests, a rodent is   
subjected to an inescapable stress leading to a “behavioural 
despair” and, when repeated, the depressive behaviour is 
increased. Thus, in the learned helplessness test, infusion of 
BDNF led to a significant improvement of the conditioned 
avoidance behaviour measured as a decrease in the number 
of failures and latency to escape, being this effect of a simi-
lar magnitude to that of imipramine or fluoxetine effect [37]. 
In the forced swimming test, acute BDNF infusion also im-
proves antidepressant-like behaviour, decreasing immobility 
and increasing the swimming behaviour [37, 111]. These two 
studies suggest a clear antidepressant-like effect of BDNF 
treatment at midbrain and hippocampus regions, respec-
tively. However, this effect seems to be specific to certain 
brain areas because BDNF infusion into the ventral tegmen-
tal area or in the nucleus accumbens, for example, increases 
depression like-behaviour. In addition, this behaviour is re-
versed by the inhibition of BDNF signalling producing an 
antidepressant-like effect [112]. These findings are in 
agreement with the stress-induced increase of BDNF expres-
sion in prefrontal cortex as mentioned before [108] and are 
the opposite to the effect observed in the hippocampus, sug-
gesting that BDNF antidepressant effect is area-dependent. 
On other hand, they could suggest that BDNF downstream 
signalling mechanisms are differently regulated and that this 
is the reason for the finding of discordant effects, but it is 
clear that there is something more to the solely and general 
enhancement of BDNF levels.  
  What seems consistent through the literature available is 
that BDNF infusion in the hippocampus or/and the midbrain 
produces antidepressant-like behavioural effects and that 
most of clinically effective antidepressant drugs work through 
this mechanism. Thus, considerable work has been devoted 
to study the effect of antidepressants on BDNF expression, 
and it appears that antidepressants, even mechanistically 
different, produce an increase of BDNF mRNA levels in the 
hippocampus after several weeks of treatment that coincides 
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The Relationship Between BDNF and Antidepressants 
  BDNF modulation could represent a key step in the adap-
tative changes brought by antidepressants. Indeed, BDNF 
increase has been reported for selective serotonin reuptake 
inhibitors (SSRIs), noradrenaline reuptake inhibitors (NRIs), 
serotonin and noradrenaline reuptake inhibitors (SNRIs) 
(dual-action antidepressants and tricyclic antidepressants), 
with monoamine oxidase inhibitors (MAOIs), atypical anti-
depressants, as well as with electroconvulsive shock treat-
ment, one of the most clinically effective treatments for   
refractory depression (see Table 1 for references). In addition, 
other compounds which at some point have been suggested 
to pose alternative antidepressant mechanisms of action   
(different to the classical enhancement of monoaminergic 
system) enhance BDNF expression too (see Table 1). This  
is the case of the anaesthetic ketamine and even lithium.   
Ketamine, a non-competitive antagonist of ionotropic gluta-
mate N-methyl-D-aspartate receptor (NMDA), blocks NMDA 
receptor signalling leading to an antidepressant effect in both 
clinical and preclinical studies [113-116]. Lithium has anti-
depressant efficacy too and glutamatergic NMDA receptor 
signalling could be the target of its action [117-121]. Thus, 
different studies have shown that treatment with ketamine or 
lithium induces an antidepressant-like effect in the forced 
swimming test paradigm, increasing BDNF protein levels in 
the rat hippocampus [122-124] (see Table 1). However, this 
needs to be further evaluated since recent studies have not 
found such modification in BDNF levels [91, 114]. 
  Antidepressants, in addition to improve or just modify 
signalling pathways, may help critical systems to overcome 
challenging conditions, that is, they may contribute to the 
neuronal plasticity that is required to cope and adapt to 
stressful situations. These could be the prime effects on 
BDNF because it responds to rapid or more prolonged ma-
nipulations and represents a key mediator for neuronal plas-
ticity that is necessary to respond to external stimuli like 
stressful conditions. Thus, how antidepressants modify 
BDNF levels? Several studies have been performed trying to 
understand the signalling pathways implicated. The effects 
on BDNF are complex and may occur at several levels. 
Therefore, antidepressants appear to increase the tyrosine 
autophosphorylation of TrkB receptors, activate phospholi-
pase-C (PLC) signalling and subsequent phosphorylation 
of CREB [19]. These data account for the effect of antide-
pressants in “resting conditions” promoting TrkB activation. 
However, and more interestingly, are there effects in 
stress/depression models? Indeed, it has been recently dem-
onstrated that duloxetine chronic treatment specifically in-
creases the mRNA levels of BDNF exon VI and exon IX in 
the hippocampus upon acute stress, whereas other isoforms 
like IV were up-regulated both in vehicle and duloxetine-
treated animals [96]. These data may account once again for 
changes in specific BDNF isoforms that may contribute to an 
adequate response to stress. In conclusion, antidepressants 
may have a potential impact on activity-dependent plasticity 
within regions involved in emotional processing, which is 
compromised in depression. Antidepressants may promote 
neuroprotective pathways and render them more responsive 
to preserve cell functionality and overcome cellular resil-
iency. The ultimate consequence of this is that antidepres-
sants would help the patient to deal with adverse situations. 
Hippocampal Neurogenesis, Antidepressants and BDNF 
  Adult neurogenesis is defined as the development of new 
functioning neurons in the adult brain, which occurs in two 
neurogenic regions, in the dentate gyrus of the hippocampus 
and the olfactory bulb. This process has been described for all 
mammalian species investigated, including non-human pri-
mates and humans [125], and although it decreases with age, 
appears to remain present at low levels even at the oldest ages 
[125-132]. From these two areas that keep the ability to gener-
ate new neurons, the whole attention in depression-related 
research has been mainly devoted to the hippocampus.  
  There are several reasons for this that will be detailed 
below, but perhaps the surprising up-regulation of neuro-
genesis by antidepressant treatment, timely coinciding with 
the onset of the behavioural antidepressant effect, is the most 
relevant. Thus, we will focus in adult hippocampal neuro-
genesis in this review. It is originated from precursor cells in 
the subgranular zone (SGZ) in the dentate gyrus and these 
new neurons extend dendrites to the molecular layer and 
axons to the CA3 pyramidal layer, getting morphological and 
physiological characteristics of adult granule cells. This new 
neurons in the adult hippocampus might contribute to opti-
mize the strength of the highly plastic mossy fibbers connec-
tion between the dentate gyrus and area CA3, and are thus 
exerting a function at a bottleneck in the hippocampal net-
work. They have been linked to the processing of informa-
tion in the sense of forming temporal associations and inte-
grating information into contexts, and also play a role in af-
fective behaviour, underscoring the link between cognition 
and emotion in the hippocampus. Thus, negative emotional 
interventions, such as stress or depression animal models, 
have shown to impair neurogenesis as well as BDNF expres-
sion in the hippocampus. Indeed, exposure to acute or   
repeated stress, including social defeat, predator odour,   
restraint, immobilization, footshock, prenatal stress and 
chronic mild stress decrease neurogenesis in the adult hippo-
campus [57]. In addition, Malberg and Duman, have ob-
served that the down-regulation of neurogenesis induced by 
inescapable stress correlates with behavioural despair in the 
learned helplessness paradigm [133]. Thus, this established 
correlation may indicate that there is a relationship between 
reduced neurogenesis and the behavioural state of the   
animal.  
  As mentioned previously, neurotrophic factors, particu-
larly BDNF [134], are known to be implicated in adult neu-
rogenesis and plasticity. However, evidences suggested that 
BDNF has a role in neuronal survival but not in proliferation 
[135], which was later corroborated in BDNF heterozygous 
and TrkB transgenic mice [136]. Additionally, it is known 
that neurogenesis is modified by many factors, including 
aging which dramatically decreases adult hippocampal neu-
rogenesis, and corticoids. In fact, corticoids have been shown 
to decrease BDNF levels in the hippocampus. In addition, 
already in 1992, it has been demonstrated that glucocorticoids 
hormones suppress cell division in the adult dentate gyrus, 
which indicated that modifying corticosteroids levels might 
possibly increase hippocampal neurogenesis [137]. It is also 
recognized that the generation of neurons is increased by 
environmental and behavioural interventions that have a 
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in mice exposed to an enriched environment, in line with an 
increase in BDNF expression, presenting more new neurons 
in the dentate gyrus and a larger hippocampal granule cells 
layer compared with mice housed in standard cages [138, 
139]. Physical exercise appears to also have a positive effect 
on adult hippocampal neurogenesis and BDNF expression as 
it has been reported that running doubled the number of sur-
viving newborn cell, in amounts similar to enrichment condi-
tions [140, 141]. These preclinical studies go along with 
clinical evidences showing a therapeutic response of exercise 
on mood in depressed patients [142-147]. Altogether, it ap-
pears that newly generated neurons in the dentate gyrus in 
the adult hippocampus are affected by the hippocampal-
dependent memory formation and BDNF regulation and may 
also be implicated in mood and cognition [148, 149].  
  The finding that antidepressant treatment increases neu-
rotrophic factor expression and hippocampal neurogenesis 
provided the background and rationale for the neurotrophic 
theory of depression, as mentioned before. Indeed, both in 
vivo and in vitro studies have supported the notion that 
chronic but not acute antidepressant treatment (fluoxetine, 
reboxetine, tranylcypromine, clomipramine, imipramine but 
not desipramine) induces an increase of bromodeoxyuridine 
(BrdU, a thymidine analog, marker for dividing cells) posi-
tive cells number, increasing the proliferation of hippocam-
pal cells and their maturation progress to become adult gran-
ule cells. Given that stress induces atrophy and loss of hip-
pocampal cells which contribute to the pathophysiology of 
depression, and that antidepressant treatment is able to over-
come these negative effects by increasing the proliferation 
and neuronal number, it is possible that such events contrib-
ute to the therapeutic actions of antidepressants drugs [60, 
150]. Equally, the electroconvulsive therapy and lithium, 
also increase hippocampal neurogenesis [59, 151]. There-
fore, it seems that compounds or other therapies used for 
depression treatment improve the pathophysiology of de-
pression probably by increasing adult hippocampal neuro-
genesis. However, it still remains an open question how adult 
neurogenesis modulates mood and how antidepressants work 
under this pathway. Concerning this issue, an elegant hy-
pothesis about a functional differentiation along the septo-
temporal axis in the hipoccampus has been developed [61]. 
The authors suggest that neurogenesis in the ventral dentate 
gyrus may be preferentially involved in the regulation of 
emotion and the dorsal pole would be modulating learning 
processes [61]. In such way, the ventral pole would project 
to mood related areas, such as prefrontal cortex, amygdala, 
nucleus accumbens. In addition, it is known to possess a very 
dense serotoninergic innervation, compared with the dorsal 
part, and a specific topography of mossy cells and hilar in-
terneurons [152]. Furthermore, the exposure to chronic mild 
stress decreased cell proliferation in the ventral but no in 
dorsal dentate gyrus, being this effect specifically reversed 
by the SSRIs escitalopram [153]. These data are promising 
to understand hippocampus involvement in mood regulation 
and possibly in the pathophysiology of depression, although 
the role of BDNF in this putative hippocampal functional 
division is still unknown. 
  From available evidence, we could suppose that there is a 
unique and bidirectional pathway from illness to the recov-
ery that implicates BDNF and hippocampal neurogenesis. 
However, we are still far away from proving that. In fact, 
several papers have shown that neurogenesis is not required 
for the emotional beneficial behavioural effects of the anti-
depressant fluoxetine in a highly anxious mice strain [154], 
or of a melanin related compound [155] or even of environ-
mental enrichment [156]. Moreover, several clinical and 
preclinical studies have suggested that opioids also have a 
genuine antidepressant effect [157, 158], and therefore it 
could be possible that they would induce increased neuro-
genesis as well. However, chronic administration of mor-
phine and heroin opiates, decrease, instead of enhancing, 
adult hippocampal neurogenesis by about 40% in the granule 
cell layer [159]. Regarding BDNF hippocampal expression, 
there is evidence that acute intracerebroventricular admini-
stration of opioids increase it [160], but there is no results 
available about the effect of chronic treatment. Accordingly 
to these data, it could be suggested that the decrease of new 
neurons formation might be associated to the negative effects 
of these drugs of abuse, or that the antidepressant effect of 
opioids is independent of neurogenesis. While waiting for 
further studies that may clarify this and other points, we can 
consider that perhaps a plausible explanation is that there are 
hippocampal (and neurotrophic) dependent and independent 
mechanisms involved in the antidepressant effect of classical 
antidepressant drugs, and that hippocampus neurogenesis   
is one of the modulator mechanisms that favour mood   
recovery. In this line, it is still a matter of discussion if   
the effect of antidepressants on neurogenesis involves   
always neurotrophins. As a matter of fact, a recent study   
has shown that noradrenaline activates self-renewing and 
multipotent neural precursors, including stem cells, by   
directly acting on beta-3 adrenergic receptors of the sub-
granular hippocampal zone [161]. Additionally, it is still less 
clear, at least at the moment, if a reduction of this neurogenic 
process is underlying human depression.  
Lessons from Mutant Animals 
  As in many other areas in neuroscience, transgenic ani-
mals have been used to elucidate the role of endogenous 
BDNF and TrkB activation on the antidepressant response. 
In this way, Saarelainen [162] used TrkB.T1 transgenic   
mice which over express the dominant-negative TrkB.T1 
isoform in neurons of the hippocampus and cortex, showing 
a reduced TrkB signalling in the brain. They have found no 
differences in immobility behaviour in the forced swimming 
test between transgenic and wild-type mice, but when   
imipramine or fluoxetine antidepressant treatment were   
administrated, they could not observe any significant effect 
on the immobility behaviour of transgenic animals [162]. 
This result suggests that the decline of this signalling   
pathway does not have a main effect on mood models   
or at least in this model of “behavioural despair” but   
that inhibition of TrkB signalling leads to a transgenic   
mouse insensitive to the behavioural effects typical of anti-
depressant drugs. However, given that TrkB receptor can be 
activated by both BDNF and NT-3, the next logical step was 
to explore, in the same paradigm, specific BDNF or NT-3 
deficient mice without any pharmacological treatment. To 
achieve this, heterozygous NT-3
+/- and BDNF
+/- mice were 
used, because homozygous mice die early during postnatal 
development [163, 164]. Thus, NT-3
+/-, but interestingly   
not the BDNF
+/-  mice, showed a normal response to anti- 
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depressant treatment induced TrkB autophosphorylation,   
and this phosphorylation correlated with the behavioural 
response of antidepressants [66, 162]. Overall, these findings 
suggest that antidepressant drugs response takes place 
through subsequent signalling by TrkB receptor activation in 
a BDNF-dependent manner.  
  In conditional BDNF knockout (KO) mice, in which 
BDNF has been deleted in broad forebrain regions, Monteg-
gia and collaborators have demonstrated that loss of BDNF 
in both male and female mice attenuates the actions of the 
antidepressant desipramine in the forced swimming test 
[165]. Studies have also examined whether the loss of BDNF 
signalling, by impairing the function of the TrkB receptor, 
influences depression-like behaviour. Conditional TrkB KO 
mice, in which TrkB expression was deleted in the forebrain, 
resulted in an indistinguishable level of immobility time in 
the forced swimming test compared with wild-type mice 
[166]. Moreover, transgenic mice overexpressing the full-
length neurotrophin receptor TrkB (TrkB.TK+; isoform re-
sponsible for most known effects of TrkB activation) exhibit 
increased activation of the TrkB/PLC pathway, reduced 
anxiety and depressive-like behaviour and facilitated learn-
ing [73, 167]. Taken together, these findings support the no-
tion that forebrain BDNF may be important in mediating 
antidepressant efficacy and that the increase of BDNF levels 
is sufficient to produce an antidepressant response. Addi-
tionally it appears that activation of TrkB plays a critical role 
in the behavioural responses to antidepressant drugs, but that 
the lack of TrkB is not enough to produce depressive-like 
behaviours. Therefore, as other studies suggest, also the use 
of transgenic animals indicate that BDNF-mediated TrkB 
activation is required for the antidepressant behavioural re-
sponse of antidepressants in behavioural paradigms. In addi-
tion, it has been recently proposed that BDNF may have a 
permissive role in mediating hippocampal dentritic remodel-
ling in CA3 pyramidal neurons, since BDNF(+/-) mice   
were unable to modify their dentritic structure due to chronic 
restraint stress [76]. 
  Recently, the protein p11 has received a particular atten-
tion by the scientific community researching the mechanisms 
of depression pathophysiology. The protein p11 is abun-
dantly expressed in hippocampal GABAergic interneurons 
and it is down-regulated in human and rodent depressive-like 
states and increased after chronic antidepressant treatment. 
p11 KO mice are insensitive to the antidepressant actions of 
BDNF, suggesting this protein is important to mediate the 
antidepressant-like effects of BDNF [168], and show in-
creased levels of markers for immature neuronal cell survival 
and neurogenesis [169]. Moreover p11 KO mice have an 
attenuated response to fluoxetine in measures of neurogene-
sis and in a neurogenesis-dependent behavioural test [169].  
  Transgenic mice for the serotoninergic system have also 
been useful in elucidating some of the neurotrophin-
mediated mechanisms of depression. Accordingly, it has 
been recently demonstrated that serotonin transporter (SERT) 
KO rats, which show a depressive-like behaviour, have re-
duced BDNF expression in the hippocampus and prefrontal 
cortex [170]. Additionally, chronic treatment with the anti-
depressant duloxetine restored the expression of BDNF 
mRNA-coding exon (IX) in the hippocampus and prefrontal 
cortex of SERT KO rats through the modulation of selected 
neurotrophin transcripts, whose expression was up-regulated 
by duloxetine only in SERT KO rats [171]. The authors thus 
suggest that the region and isoform-specific increase of 
BDNF levels may be important to fix normal plasticity that 
is probably defective in SERT KO mice 
  Overall these studies in transgenic animals are providing 
insights about the signalling mechanisms implicated in 
BDNF-action. Although further studies are still required, the 
results available until now suggest that BDNF is necessary 
for a response to antidepressant treatment but that partial or 
conditional BDNF deletion is not sufficient to produce a 
depressive-like phenotype. 
Clinical Evidences  
BDNF in Depressed Patients and Related Post-Mortem 
Studies 
  In most clinical studies BDNF levels have been found to 
be consistently lower in depressed patients than in healthy 
volunteers [172-179] (review in [180]). These decreases are 
in some cases correlated with higher scores in specific de-
pression evaluation scales [172]. In post-mortem studies, 
reductions in the expression of pro-BDNF were also seen 
unilaterally in formalin-fixed paraffin-embedded sections in 
the hippocampus, but not in dentate gyrus, of MD subjects 
[181]. There are some exceptions though, with a few studies 
reporting no differences in plasma or serum BDNF levels 
between depressed patients and healthy controls [182, 183]. 
Indeed, serum BDNF levels were lower in bipolar disorder 
patients during an acute depressive episode than in patients 
diagnosed for MD [182]. Some studies also suggest a gender 
specificity in what concerns BDNF levels during depression 
[173, 175]. Thus, although the application of the Hamilton 
Depression Rating Scale (HDRS) scores did not detect sig-
nificant gender differences, both healthy and depressed 
males showed higher serum BDNF levels than female sub-
jects [175].  
  Biochemical data has also been consistent in indicating a 
restoration of BDNF levels following antidepressant therapy 
[177, 178, 184, 185] (review in [180]). Some studies indicate, 
however, that the changes in BDNF concentrations depend 
on the antidepressant administered instead of being a general 
output of antidepressant treatment [186]. The mechanisms 
contributing to such augment of BDNF upon antidepressant 
therapy are poorly studied in humans. Nevertheless, the 
study of Cattaneo and colleagues [184] indicates that BDNF 
serum increases upon antidepressant treatment are associated 
with changes in BDNF mRNA levels in leukocytes, suggest-
ing that these cells might play an active role in the mecha-
nisms of action of antidepressant drugs and perhaps may be 
used as a specific biomarker in the future. Additionally, there 
is also some evidence that the efficacy of atypical anti- 
psychotics as adjuvant to commonly used antidepressants in 
refractory depressed patients might involve an increase of 
plasma BDNF levels [187]. Also, it was found that endur-
ance training induced increased BDNF levels in the hippo-
campus and an enhanced release of BDNF from the human 
brain [188]. Indeed, these findings might be related with   
the beneficial effect that physical exercise seems to have on 
depressed patients [142-147]. But then again, there is data 
against this. In fact, BDNF plasma levels were found to be 
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patients with moderate depression. This rise, however, was 
not correlated with improved depression scores, and was of 
the same magnitude as that observed in healthy subjects, 
which may be due to the fact that no differences were found 
in BDNF levels between patients and controls prior to exer-
cise [183]. Sleep deprivation, as adjuvant to antidepressant 
therapy, seems equally to be associated with increases in 
BDNF levels [172, 176]. On the other hand, electroconvul-
sive therapy in depressed patients has been shown to either 
increase [176, 189], and in remitter patients even restore 
[176] BDNF levels, or on the contrary to have no effect on 
BDNF expression [190]. 
  Clinical studies have indicated a relevant association of 
MD with a significant neuronal atrophy, especially at the 
hippocampal level [191-193] (more references in the review 
[194]). This hippocampal degeneration is most likely corre-
lated with the reduced trophic support, as suggested by find-
ings of decreased BDNF and other neurotrophins in post-
mortem hippocampal tissue of MD patients and suicide vic-
tims [181, 195] (review in [196]). Antidepressant therapy, by 
mechanisms that seem to promote increases in BDNF hippo-
campal levels and adult neurogenesis, has been shown to 
block or reverse the loss of hippocampal volume [197] (re-
views in [196, 198]), as already discussed. Thus, one ques-
tion that has aroused from animal and these clinical findings 
is that the decrease of neurogenesis may be one of the causal 
factors of depression. Yet, we still do not know whether den-
tate gyrus function is altered in depressed patients and 
whether this is restored with the antidepressant treatment. 
There are just three studies available on depressed patients. 
Reif and collaborators [199] failed to find changes in prolif-
eration in depression, and antidepressant treatment had   
no effect. In contrast, Boldrini [200] found a reduction in 
proliferation in non-treated depression whereas antidepres-
sant-treated patients showed higher proliferation numbers. 
There is a third report in elderly patients that has found de-
creased proliferation and reduction in the number of progeni-
tor cells but in agreement with Reif’s study has not found 
any stimulatory effect upon antidepressant treatment [201]. 
This discordance may be related to the type of antidepressant 
medication in combination with the age of these patients. 
Hence, further studies in preferably larger patient groups are 
warranted. From a structural point of view, recent data also 
indicate that even healthy subjects with increased risk for 
developing depression, either due to familial predisposition 
or childhood neglect-induced stress, have reduced hippo-
campal volumes [202-204]. This suggests that lower hippo-
campal volumes in healthy individuals might indicate a ten-
dency to develop depression [191-192, 202-205] and thus 
imaging studies may become useful tools to predict a future 
onset of the disorder. However, it seems unlikely that puta-
tive reductions in hippocampal volume are related with neu-
rogenesis because animal studies have shown that volumetric 
modifications are due to reduced dentritic complexity and 
not to the impairment of new neurons born [206]. However, 
although not being a consequence may be a co-existent fact. 
Another reason that discourages the view of decreased hip-
pocampal neurogenesis or BDNF levels as etiological factors 
of depression is, as mentioned before, that the blockade   
of hippocampal neurogenesis [207] or conditional deleted 
expression of BDNF in male mice [165] do not induce a   
depressive-like behaviour. Nevertheless, it is still unknown  
if it is a predisposing factor, that is, if the combination   
of impaired neurogenesis with genetic predisposition or   
environmental factors triggers depression appearance. Thus, 
the role that genetic and environmental factors play together 
with neurogenenesis and the contribution of each to a future 
development of the disease is still an issue that needs further 
investigation.  
BDNF Polymorphisms in Depression  
  The search for variations at the BDNF gene has resulted 
in the identification of several single nucleotide polymor-
phisms (SNP) but the rs6265 has been the mostly studied 
until now. This polymorphism is located at nucleotide   
position 196 of the human BDNF gene and consists on   
the substitution of a guanine by an adenine base, which gen-
erates the replacement of valine by methionine at codon 66 
(Val66Met) in the amino acid sequence. The Val66Met 
polymorphism has been associated with abnormal intracellu-
lar trafficking and regulated secretion of BDNF in cultured 
hippocampal neurons [208]. Also, there is some piece of 
evidence suggesting that human subjects having the Met 
allele in the BDNF gene have abnormal hippocampal activa-
tion [208] as well as poorer episodic memory [208] and ver-
bal recognition memory [209]. Other studies of small human 
cohorts have equally shown that subjects carrying the Met66 
allele have smaller hippocampal volumes than Val/Val ho-
mozygotes [210-212]. Additionally, reduced grey matter 
volumes were also observed in the thalamus, parahippocam-
pal gyrus and amygdala of Met66 allele carriers [211].   
Conversely, by studying a large cohort of healthy human 
individuals, others have found that the BDNF Val66Met 
genotype is unrelated to hippocampal structure or memory 
performance [213]. Additionally, other studies have equally 
failed to show a link between the Val66Met polymorphism 
and memory function [214], and quite on the contrary, have 
associated carriers of the Met66 allele with better cognitive 
functioning in the psychomotor and motor domains, suggest-
ing that this allele may confer neuroprotection against the 
decline of these cognitive functions, at least in patients with 
systemic lupus erythematosus [215]. In what concerns major 
depression, Frodl and colleagues [205] have found signifi-
cantly smaller hippocampal volumes in depressed patients, 
but also in healthy controls, carrying the Met66 BDNF allele 
compared with Val/Val homozygotes, concluding that the 
presence of a Val66Met BDNF polymorphism may predis-
pose human carriers to develop smaller hippocampal vol-
umes and depressive disorders. Reduced grey matter hippo-
campal volume in Met66 carriers was also associated to ele-
vations in trait depression [216]. However there is some dis-
crepancy among different studies concerning the association 
between the Val66Met BDNF polymorphism and reduced 
hippocampal volumes in major depression. As an example, 
Jessen and partners [191] did observe reduced hippocampal 
volumes in major depressed patients but an effect of the 
presence of a Met66 allele on hippocampal volume was not 
found in either depressed or healthy subjects. Similarly, in 
depressed elders, the BDNF Val66Met polymorphism was 
also not significantly associated with smaller hippocampal 
volumes or impaired cognitive function [217]. Therefore the 
authors suggest geriatric depression may be mediated 
through other mechanisms [217]. It is important to note that 
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poorer execution of memory tasks [213, 218], as well as re-
duced levels of serum BDNF [218]. 
  Whether the presence of particular BDNF polymor-
phisms predisposes the individual for having major depres-
sion is a question still under investigation (short review in 
[219]). Indeed, work in rodents support the idea that the 
Val66Met polymorphism may serve as a genetic predictor of 
future development of depressive disorders [220-221]. In 
humans this is corroborated by some studies indicating that 
Met66 allele carriers are more liable to have geriatric depres-
sion than do Val66 allele homozygote individuals [222-224]. 
Additionally, the BDNF Val66Met polymorphism has been 
associated with major depression [225], a risk for suicidal 
behaviour [226, 227] as well as with rumination in healthy 
adults [228], a behaviour characterized by the tendency to 
brood and repetitively think about negative information, that 
is correlated with depression [229]. However, other reports 
indicate no obvious association of this BDNF variant with 
the disease itself [230-232], but there seems to be a relation 
of Val66Met polymorphism to the levels of BDNF. Another 
matter of discussion is the correlation with the gender of the 
individual, occurrence of a BDNF polymorphism and risk for 
developing depression. A recent meta-analysis study re-
vealed that the BDNF Val66Met polymorphism is not sig-
nificantly associated with depression or with ethnic factors, 
but seems related with gender, so that the presence of the 
polymorphism, may predispose the development of major 
depression in men more than in women [232]. However, a 
similar gender effect was not found by Ozan and colleagues 
[175]. In fact it was not detected any association between 
Met-carriage and mental health status, as evaluated by the 
Hamilton Depression Rating Scale (HDRS), as well as any 
gender effect on HDRS scores in the patients. The authors 
reported, however, that both patients and healthy controls 
carrying the Val66Met polymorphism exhibited lower 
BDNF serum levels than Val homozygote subjects, but this 
was observed regardless of gender [175]. The connection 
between carrying a BDNF polymorphisms and the individ-
ual’s response to antidepressant therapy is also being evalu-
ated by some researchers but to a lesser extent. Indeed, ge-
netic factors are thought to play a key role in both variation 
of response to treatment and incidence of adverse effects to 
medication (for review see [233]). Domschke and partners 
[234] found that the rs7103411, Val66Met (rs6265) and 
rs7124442 BDNF polymorphisms are related with worse 
response to antidepressant treatment over 6 weeks in major 
depression, particularly in the melancholic depression (for 
rs7103411 and Val66Met) and anxious depression (for 
rs7124442) clinical subtypes. However other studies report a 
significantly better therapeutic effect to citalopram [235], 
milnacipran or fluvoxamine [236] antidepressant drugs in 
Met66 allele carriers. Moreover, the Val66Met BDNF vari-
ant was also found to be associated with better efficacy in the 
treatment of depressed patients by repetitive transcranial 
magnetic stimulation (rTMS) [237]. 
  Evidence suggests that BDNF can enhance serotoninergic 
transmission (review in [238]). In fact, BDNF promotes the 
survival and differentiation of 5-HT neurons whereas ad-
ministration of SSRIs increases BDNF expression. Addition-
ally, both BDNF- and serotonin-mediated signalling regulate 
the development and plasticity of neural circuits involved in 
mood disorders such as depression and anxiety [238]. It is 
crucial then to not overlook the genetic impact of carrying 
serotonin transporter (5-HTT) gene polymorphisms on de-
velopment of depression, nor the possible interrelation with a 
BDNF polymorphism. Indeed, evidence suggests that indi-
vidual genetic variability and the interaction between 5-HTT 
and BDNF polymorphisms may account for an increased risk 
to develop depressive-like symptoms. In their case-only de-
sign study of ethnically homogenous patients diagnosed with 
first episode depression, Bukh and partners [239] independ-
ently associated the existence of both low activity variants of 
the 5-HTT-linked polymorphic region in the serotonin trans-
porter gene and the Val66Met BDNF polymorphism with the 
presence of stressful life events prior to onset of depression. 
Similarly, the interaction between the 5-HTTLPR serotonin 
transporter polymorphism and Val66Met BDNF gene variant 
was significantly associated to depression originated by 
stressful factors occurring either in childhood [240, 241] or 
adult life [242]. 
  As a conclusion, there is some clinical evidence for an 
important effect of the genetic variability in BDNF and sero-
tonin transporter genes on the risk to develop depressive 
behaviours and depression-associated mood disorders, such 
as suicide. Additionally, there seems to exist and interaction 
between these two genes, especially when early childhood 
and adult stressful events are present. Data also indicate   
that the Val66Met BDNF polymorphism is associated with  
alterations in brain anatomy and memory performance, and 
also that it might play a role on the individual response to 
antidepressant therapy. There are, however, studies that do 
not corroborate these findings. The different analytical ap-
proaches between the various studies, especially in what 
respects the size of the sample analyzed, the clinical scales 
used for diagnosing the existence and/or severity of mood 
disorder and the discrimination for different racial, gender 
and age characteristics may account for such discrepancies. 
NEUROTROPHINS AS COMMON PHARMACOL-
OGICAL TARGETS FOR DEPRESSION AND OTHER 
NEUROPSYCHIATRIC DISEASES: ALZHEIMER’S, 
PARKINSON’S, SCHIZOPHRENIA AND BIPOLAR 
DISORDER 
  Apart from their role in the pathophysiology of depres-
sion, neurotrophins seem to be implicated in other neuropsy-
chiatric diseases as well, suggesting they might be a common 
target in the mechanisms causing these different neuropa-
thologies. Actually, epidemiological and neurobiological 
evidences support a strong relationship between depression 
and dementia and several common pathophysiological 
mechanisms have been described some of them involving 
neurotrophin signalling (for review see [243]). In the initial 
stage of Alzheimer´s disease (AD), for example, cognitive 
impairment is often accompanied by mood instability and 
depressive symptoms [244] and the prevalence of AD is 
higher in persons with a history of major depression [245]. 
Several data lead to the hypothesis that BDNF deficiency 
might be one of the bridges between AD and major depres-
sion [246]. Indeed, beta-amyloid (Abeta) protein deposits, 
which are observed in AD patients, seem associated to 
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Analysis of BDNF content in the serum of 30 patients at two 
different stages of AD dementia revealed BDNF values are 
increased in early stages of AD, while they decrease with the 
course of the disease, correlating with the severity of demen-
tia [247]. The authors speculate that this peculiar pattern of 
BDNF content changes may represent a compensatory repair 
mechanism triggered by neurodegeneration in the initial 
stages leading to increased degradation of Abeta, while at 
later stages the decreases may account for a deficient trophic 
support causing Abeta deposition and progressive neurode-
generation [247]. Western blot analysis of post-mortem pa-
rietal cortex tissue from AD patients has revealed, however, 
that BDNF levels are reduced already at early stages of dis-
ease, which was correlated with loss of cognitive function 
[248]. These differing findings concerning the levels of 
BDNF at early stages in AD patients raises the need for more 
investigation, but studies in transgenic mouse models of AD 
suggest that the decreased BDNF expression is dependent on 
the aggregation state of Abeta as well as on large Abeta oli-
gomers [249]. Studies in rodents also show a close associa-
tion between BDNF expression and Abeta. Thus, intrahippo-
campal injections of aggregated Abeta(1-42) abolished the 
increase in serum BDNF levels and induced a significant 
decrease of BDNF levels in frontal cortex suggesting im-
paired BDNF regulation during AD [250]. More recently, the 
administration of Abeta(1-42) induced a decreased NGF and 
BDNF expression in the prefrontal cortex along with a de-
pressive-like behaviour in rats detected by increases in the 
forced swimming test immobility [251]. The use of trans-
genic mouse models of AD indicates that Abeta reduces 
BDNF signalling by impairing its axonal retrograde transport 
[252], therefore causing reduced activation of specific recep-
tors. But BDNF is not the only neurotrophin that seems in-
volved in AD. NGF protein levels are also dysregulated in 
brain tissues from AD patients, and loss of its tyrosine kinase 
A (TrkA) receptor has also been reported (for review see 
[253]). As for BDNF, the microtubule-dependent retrograde 
trafficking of NGF appears to be defective, both in models of 
age-dependent cholinergic degradation (the aged Fischer 344 
rat model, which shows cognitive impairment [254-256]) 
and transgenic models of Down’s syndrome and AD [257, 
258]. In what respects glial cell line-derived neurotrophic 
factor (GDNF) the sparse available studies also indicate its 
levels are changed in cerebrospinal fluid and serum of pa-
tients with early Alzheimer's disease [259]. Other neurotro-
phin that seems somehow related both with major depression 
and AD is tumour growth factor beta 1 (TGF-1) [243].   
Although TGF-1 is mainly recognized as anti-neuronal   
survival, their effects occur via Trk receptor signalling and 
possibly by interacting with BDNF as a co-factor [260]. 
TGF-1 increases BDNF and Trk expression [260] and   
reduces NT-3 mRNA levels [261]. Levels of serum TGF-1 
and the allele and genotype frequencies distribution were 
unchanged in AD patients in comparison to controls [262]. 
However other investigators found these levels were depend-
ent on the disease progression, being higher in the plasma  
of AD-mild patients, less higher in AD-moderate patients 
while no differences were detected between severe AD in 
comparison to age-matched subjects with no clinical signs of 
dementia [263]. Also in the TgCRND8a mouse transgenic 
model of familial AD, TGF-1 content was up-regulated in 
cortical brain regions [264]. The low-affinity p75NTR seems 
also to be an important therapeutic target in order to prevent 
or ameliorate the symptoms of neuropsychiatric degenerative 
diseases. Indeed, mice lacking p75NTR show several altera-
tions in central nervous system and cognitive function   
[265]. Some authors suggest that the increase in the levels of 
proneurotrophins found in AD, both pro-BDNF and pro-
NGF but in particular pro-NGF, may cause p75-mediated 
neurotoxicity and cellular apoptosis, typically associated to 
neurodegenerative pathologies. Additionally, the low TrkA 
to p75 ratio detected in AD patients enhances the activation 
of p75 by neurotrophins, proneurotrophins as well as Abeta 
(which has also been found to bind p75), equally contribut-
ing to boost neuronal death through p75 signalling (for   
review see [266]). 
  Although there is considerably more information avail-
able on Alzheimer’s disease, there is also evidence for 
changes in neurotrophins content occurring in the course of 
other neurogenerative pathologies such as Parkinson’s dis-
ease, schizophrenia and bipolar disorder (for review see 
[267-270]). By employing a multi analyte profiling pro-
teomics approach in plasma samples from schizophrenic 
patients, Domenici and colleagues have found that BDNF 
may be a candidate biological marker for schizophrenia 
[271]. However there are some contradictory findings con-
cerning BDNF levels in schizophrenia. Thus, increased se-
rum BDNF levels were found in schizophrenic patients that 
had been chronically medicated with clozapine or other typi-
cal and a typical antipsychotics in comparison to healthy 
controls or to euthymic bipolar disorder patients. The authors 
suggest that these findings could be related to the course of 
the disease itself or to the effects of medication [272]. In 
contrast, other studies reported decreased serum BDNF lev-
els in schizophrenic patients that had also been treated with 
clozapine or other antipsychotics [273, 274], in accordance 
with most of the published studies (for references see tables 
1 and 2 on [274]). Decreased serum levels of BDNF have 
also been found in patients with schizophrenia at the onset of 
the first episode [275] or during a relapse [276], while no 
changes were detected after 6 months of treatment with typi-
cal and atypical antipsychotics when compared to their own 
levels at the beginning of the study [276]. This implies that 
the therapeutic strategies followed had no effect on BDNF 
levels. To add some more controversy to the issue, findings 
of no changes in plasma BDNF from schizophrenic patients 
compared to healthy controls have also already been de-
scribed [38, 277]. There are not so much studies addressing 
the role of neurotrophins in bipolar disorder but those avail-
able report no differences in BDNF levels in serum from 
patients in euthymia phase compared to healthy controls 
[272, 278], but decreases were detected during depressive 
and manic episodes (for review see [267]). Concerning Park-
inson´s disease, studies have been addressing the effects of 
GDNF (or of other ligands of the family, as neurturin) deliv-
ery both in experimental animal models of the disease and in 
clinical trials, in order to amend the disease symptoms and 
enhance the morphological differentiation and survival of 
dopaminergic neurons. Nevertheless there are still many 
steps to go through before reaching major enthusiastic clini-
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  In conclusion, the available data indicate that many neu-
rotrophins represent a common pathogenic factor between 
depression and other neuropsychiatric disorders. This seems 
particularly true for BDNF in the case of AD, which co-
prevalence with major depression is high. It has indeed been 
proposed by some authors that the therapeutic use of BDNF 
itself or of drugs targeting its production may constitute a 
valid alternative to treat depressed patients with cognitive 
impairment or AD concomitant with depression [246].   
Additionally, with advancing research on the role of neuro- 
trophins, this may reveal valid for other neuropsychiatric 
diseases as well. 
OTHER NEUROTROPHIC/GROWTH FACTORS IN 
DEPRESSION 
  Although not explored to such a great extent as BDNF, 
the role of other neurotrophins in the pathophysiology of 
depression is also under investigation. The vascular endothe-
lial growth factor (VEGF) is suggested to have an antide-
pressant-like effect [46, 279]. Indeed VEGF signalling medi-
ated through its Flk-1 receptor appears to be essential to in-
duce behavioural responses in chronic and subchronic anti-
depressant models and for antidepressant-induced cell prolif-
eration [46]. Lee and colleagues have also found that tran-
scription of the neuronal VEGF in hippocampal and dentate 
gyrus neurons is required to evoke antidepressant-like behav-
iours and that this is mediated by the cAMP cascade [279]. 
Clinical studies in depressed patients have inconsistently 
found increased serum levels of VEGF [280], or no changes 
when comparing control subjects and patients with major 
depression [281], either before or upon antidepressant medi-
cation [282]. In rats, VEGF protein levels were significantly 
down-regulated in the Flinders Sensitive Line model of   
depression in the hippocampus and frontal cortex and were 
unaffected in hypothalamus, corpus striatum, and serum 
[283]. The basic fibroblast growth factor (FGF2) is known to 
also have large neurotrophic activity in the adult central 
nervous system [284, 285]. Some studies also point to be 
associated with the mechanisms of action of some antide-
pressant drugs. In fact, antidepressant treatment in rats elic-
ited an increase in FGF2 mRNA and protein in various re-
gions of the brain. The increases were anatomically specific 
accordingly to the time after injection and to antidepressant 
drugs administered, but were observed in cortex and hippo-
campus of the rats [286]. Increased serum levels of FGF2 
were equally detected in medication-free depressed patients 
[280]. Indeed, there seems to exist and interplay between 
BDNF, VEGF and FGF in what concerns the mechanism of 
neurogenesis and associated angiogenesis [198]. 
  The role of NGF in depression is also a matter of   
research. Hellweg and colleagues in his prospective study 
with depressed patients found no differences in NGF serum 
levels upon antidepressant therapy [186]. However some 
data obtained in rodent models of depression indicates that 
NGF has significant antidepressant effects [287], and that 
NGF levels are decreased [288], suggesting this neurotrophin 
might also play a role in the events leading to depression. 
Also the neurotrophin-3 (NT-3), GDNF and artemin (member 
of the GDNF family) were found to have decreased mRNA 
expression in the blood of patients with major depression. 
Changes were found during the current depressive state, but 
not in a remissive state, suggesting that these neurotrophins 
might be involved in the pathophysiology of major depres-
sive disorder and that their mRNA levels are state-dependent 
[289]. Indeed NT-3 seems to be a potential candidate as   
antidepressant (for review see [290]) but more studies are 
still needed.  
  In conclusion, data reveals that a wide range of neurotro-
phic factors besides BDNF may be potential candidates for 
the development of better and with lesser side-effects treat-
ments for depression. Possibly the interplay between differ-
ent neurotrophins plays a major role on the pathophysiology 
of mood disorders, rather than the action of a sole neuro- 
trophin. It remains to establish, though, the contribution of 
each of these molecules in the events leading to depressive 
disorder and the possible link between them. More studies 
focused on these aspects, and not only on BDNF, are there-
fore needed.  
NEUROTROPHIN-INDUCIBLE NEUROPEPTIDES IN 
DEPRESSION: ROLE OF VGF 
  In the last few years, the notions on the mechanisms of 
depression have been changing. Neurotrophins appear to be 
directly associated with this disease but their indirect action, 
under pathological conditions, on other molecules must also 
not be forgotten, neither the action that these molecules 
could exert on neurotrophins. This seems to be the case of 
VGF (not an acronym), a neuropeptide highly expressed   
in brain tissue [291-295] that was already demonstrated   
to be decreased in depressed patients [296]. VGF appears to 
be the main target of some neurotrophins. Indeed, VGF was 
primarily identified as a NGF-regulated transcript [297]. 
Additionally, studies using specific antibodies to neutralize 
neurotrophins indicated that BDNF is required for VGF   
expression, at least in some brain regions [298]. Further-
more, the implication of VGF in neurotrophins-synaptic 
modulation was also suggested by observing that VGF co-
localizes with TrkB [299]. However, the roles of VGF   
in depression barely begin to be studied, being evident the 
lack of knowledge around this neuropeptide. Until know, 
data suggest dysregulation of VGF in psychiatric disorders 
[300]. Recently, Cattaneo [296] observed that depressed   
patients without treatment showed lower levels of VGF 
mRNA when compared with controls, which indicates a role 
for VGF in the pathophysiology of mood disorders. Thakker-
Varia and collaborators [301] had also reported decreased 
levels of this neuropeptide in the hippocampus after the 
learned helplessness and forced swimming test paradigms   
of depression. Thus, it became clear that somehow the   
neurotrophin-inducible neuropeptide VGF has a role and 
may constitute a target in the treatment of some psychiatric 
disorders. 
  There are some studies showing that antidepressants en-
hancing primarily the levels of serotonin in the synaptic cleft 
are also able to influence the transcription of synapse-
associated proteins and neuropeptides [302-306]. Thakker-
Varia and partners [301] showed that VGF is up-regulated 
not only by BDNF but also by serotonin. They also demon-
strated that VGF protein was diminished in the hippocampus 
of rats submitted to behavioural models of depression [301]. 
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by BDNF, the fact that the VGF gene has a CREB binding 
site [299] suggests an interaction between regulation by   
serotonin and BDNF. Indeed, after a chronic treatment with 
imipramine, it was observed an increase in VGF expression 
and, in the same way, after electroconvulsive therapy, it was 
observed an increase in VGF mRNA [307-309]. These treat-
ments were also shown to promote the increase of BDNF 
expression [74, 307, 310]. CREB was shown to be highly 
activated [311, 312] by phosphorylation of protein kinase   
A (PKA, [313]) and adenylyl cyclase [314] upon antidepres-
sants chronic administration, leading to increased levels of 
cAMP after this treatment [315]. In fact, CREB can consti-
tute a post-receptor target that can be influenced by serotonin 
and noradrenaline in the synaptic cleft [62, 312, 315-318]. 
Chen and partners [319] verified that over-expression of 
CREB in two animals models of depression resulted in anti-
depressant effect. One molecular target of CREB activation 
is the transcription of BDNF, suggesting their interconnec-
tion. Conti and collaborators [320] showed that CREB-
deficient mice do not have an altered response to de-
sipramine and fluoxetine when compared to wild type mice, 
but BDNF up-regulation was abolished. This suggested that 
during antidepressant treatment, CREB activation is up-
stream to BDNF. Moreover, it was shown a certain correla-
tion between CREB mRNA activation and BDNF mRNA 
levels along with its receptor, TrkB, after chronic administra-
tion of antidepressants [62, 74]. So, antidepressants promote 
an increase of the levels of serotonin and/or noradrenaline in 
the synaptic cleft conducing to the activation and phosphory-
lation of CREB and, consequently, leading to BDNF gene 
transcription. Additionally, these actions may be potentiated 
by the intriguing overlapping circuit observed in some 
growth factors, mainly BDNF [221, 321], which means   
that increases of BDNF expression may lead to more BDNF 
expression.  
  VGF seems to be acting downstream of BDNF by having 
an antidepressant-like effect and enhancing neurogenesis in 
the hippocampus [301]. Indeed, it is recognized that antide-
pressants may act promoting neurogenesis and that this event 
might be mediated through BDNF and activation of the 
cAMP-CREB pathway [60, 322, 323]. VGF may be involved 
in this process as indicated by the proliferation of hippocam-
pal progenitors cells, both in vitro and in vivo, upon chronic 
VGF treatment [301]. Additionally, the increase in synaptic 
activity, as observed in hippocampal cultures upon VGF 
treatment [324], may constitute an alternative mechanism 
related with VGF antidepressant-like actions. However, it 
seems likely that actions in neuronal plasticity may explain 
the short term action of antidepressants while long term ac-
tion may be due to neurogenesis. 
  Finally, the influence of exercise must be contemplated 
because of its well known benefits in improving mood in 
depressed patients. Recently, Hunsberger and colleagues 
[325] showed the involvement of exercise in the regulation 
of the VGF gene and consequently in its action as an anti- 
depressant-like agent. Indeed, exercise and the growth factor 
pathway have, as principal target, the gene encoding VGF 
which has been previously shown to influence not only   
synaptic plasticity [297], as has been discussed so far, as 
well as metabolism [326]. The administration of a synthetic 
VGF-derived peptide induced an antidepressant-like re-
sponse in mice and mutation of VGF in mice induced the 
contrary [325], suggesting that VGF signalling may consti-
tute a potential therapeutic target for antidepressant drug 
development. 
CONCLUSION 
  Depression is a complex disorder that implies multiple 
neuronal substrates and brain regions. Currently available 
antidepressants acutely increase monoamine levels but the 
chronic treatment is required for the onset of antidepressant 
effect, meaning that enhanced serotoninergic and/or 
noradrenergic neurotransmission is not the trigger factor for 
the clinical actions of these drugs. This has lead to the hy-
pothesis that long-term adaptations are necessary for their 
effects. Among several alterations of intracellular signal 
transduction pathways and target genes that may contribute, 
huge attention has received the neurotrophins regulation, 
especially BDNF. Initially, it was suggested that low levels 
of BDNF lead to a depression state. However, nowadays, 
this vision has been modified, highlighting the role of BDNF 
in the adaptation of neural networks, including neurogenesis, 
that are responsible for different aspects of mood regulation 
and antidepressant-like effect. Thus, BDNF expression 
seems to be dependent of chronic antidepressant treatment. 
In fact it is plausible that, somehow, neurotrophins may also 
have functions in the regulation of transmitter release that 
finally may account for the onset of the antidepressant effect. 
Thus, the study of neurotrophic factors modulation may pro-
vide insight into the modulation of brain function associated 
with psychiatric disorders, including depression. 
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ABBREVIATIONS 
AD =  Alzheimer´s  disease 
Abeta =  beta-amyloid 
BDNF  =  Brain-derived Neurotrophic Factor 
BrdU =  Bromodeoxyuridine 
CREB  =  cAMP-related Element Binding Protein 
ERK  =  Extracellular signal-Regulated Kinases 
FGF2  =  Basic Fibroblast Growth Factor  
GDNF  =  Glial Cell Line-derived Neurotrophic Factor 
HDRS  =  Hamilton Depression Rating Scale 
5-HT2A  =  Serotonin 2A receptors 
5-HTT =  Serotonin  Transporter Neurotrophins in Depression  Current Neuropharmacology, 2011, Vol. 9, No. 4    543 
5-HTTLPR  =  Serotonin Transporter Promoter Region 
IL-1 =  Interleukin-1 
KO =  knockout 
mBDNF =  mature  BDNF 
MAOIs  =  Monoamine Oxidase Inhibitors 
MAPK =  Mitogen-Activated  Protein  Kinases 
MD =  Major  Depression 
mGluR2/3  =  Metabotropic Glutamate 2/3 Receptors 
NGF  =  Nerve Growth Factor 
NMDA =  N-methyl-D-aspartate  receptor 
NRIs  =  Noradrenaline Reuptake Inhibitors 
NT-3 =  Neurotrophin-3 
NT-4 =  Neurotrophin-4 
PLC =  Phospholipase-C 
p75NTR =  p75  Neurotrophin  Receptor 
rTMS  =  Transcranial Magnetic Stimulation 
SERT =  Serotonin  Transporter 
SGZ  =  Subgranular Zone of Hippocampus 
SNRIs  = Serotonin and Noradrenaline Reuptake   
Inhibitors 
SNP  =  Single Nucleotide Polymorphisms 
SSRIs  =  Selective Serotonin Reuptake Inhibitors 
TGF-1  =  Tumour Growth Factor beta 1 
Trk  =  Tyrosine Kinase Receptors 
TrkA  =  Tyrosine Kinase Receptor subtype A 
TrkB  =  Tyrosine Kinase Receptor subtype B 
VEGF  =  Vascular Endothelial Growth Factor 
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